ImageneBio (IMA) Competitors $8.00 +0.61 (+8.25%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMA vs. VIRI, MGX, HURA, ZNTL, ABOS, ZYBT, IKT, SRZN, PLRX, and ARTVShould you be buying ImageneBio stock or one of its competitors? The main competitors of ImageneBio include Virios Therapeutics (VIRI), Metagenomi (MGX), TuHURA Biosciences (HURA), Zentalis Pharmaceuticals (ZNTL), Acumen Pharmaceuticals (ABOS), Zhengye Biotechnology (ZYBT), Inhibikase Therapeutics (IKT), Surrozen (SRZN), Pliant Therapeutics (PLRX), and Artiva Biotherapeutics (ARTV). These companies are all part of the "pharmaceutical products" industry. ImageneBio vs. Its Competitors Virios Therapeutics Metagenomi TuHURA Biosciences Zentalis Pharmaceuticals Acumen Pharmaceuticals Zhengye Biotechnology Inhibikase Therapeutics Surrozen Pliant Therapeutics Artiva Biotherapeutics Virios Therapeutics (NASDAQ:VIRI) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends. Which has more volatility & risk, VIRI or IMA? Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, ImageneBio has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Is VIRI or IMA more profitable? ImageneBio's return on equity of -23.94% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% ImageneBio N/A -23.94%-21.62% Do institutionals & insiders have more ownership in VIRI or IMA? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 5.9% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger earnings & valuation, VIRI or IMA? Virios Therapeutics has higher earnings, but lower revenue than ImageneBio. Virios Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-20.81ImageneBio$9.16M3.50-$49.23M-$7.68-1.04 Do analysts prefer VIRI or IMA? ImageneBio has a consensus target price of $33.67, suggesting a potential upside of 320.83%. Given ImageneBio's stronger consensus rating and higher probable upside, analysts plainly believe ImageneBio is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ImageneBio 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media favor VIRI or IMA? In the previous week, ImageneBio had 5 more articles in the media than Virios Therapeutics. MarketBeat recorded 5 mentions for ImageneBio and 0 mentions for Virios Therapeutics. Virios Therapeutics' average media sentiment score of 0.00 equaled ImageneBio'saverage media sentiment score. Company Overall Sentiment Virios Therapeutics Neutral ImageneBio Neutral SummaryImageneBio beats Virios Therapeutics on 9 of the 13 factors compared between the two stocks. Get ImageneBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMA vs. The Competition Export to ExcelMetricImageneBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.60M$3.44B$6.23B$10.68BDividend YieldN/A2.26%5.71%4.82%P/E Ratio-1.0423.9230.0629.84Price / Sales3.50487.63587.23131.17Price / CashN/A45.5737.0161.44Price / Book0.2610.4012.046.60Net Income-$49.23M-$52.62M$3.32B$276.82M7 Day Performance6.10%2.08%1.79%2.07%1 Month PerformanceN/A10.84%6.28%2.62%1 Year Performance-61.01%13.57%61.13%32.86% ImageneBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMAImageneBio2.9961 of 5 stars$8.00+8.3%$33.67+320.8%-63.6%$29.60M$9.16M-1.0470News CoverageAnalyst ForecastGap UpHigh Trading VolumeVIRIVirios TherapeuticsN/A$6.19+7.5%N/A+34.5%$119.21MN/A-22.935MGXMetagenomi3.1364 of 5 stars$3.15-5.9%$10.00+217.4%+45.5%$118.97M$52.29M-1.34236HURATuHURA Biosciences1.1805 of 5 stars$2.33-5.1%$12.67+444.8%N/A$118.81MN/A0.00N/AGap DownZNTLZentalis Pharmaceuticals2.1737 of 5 stars$1.65+6.1%$5.84+255.0%-50.6%$118.67M$67.43M-0.73160News CoveragePositive NewsAnalyst ForecastGap UpABOSAcumen Pharmaceuticals3.0057 of 5 stars$1.96-7.8%$7.00+258.1%-21.6%$118.42MN/A-0.8620ZYBTZhengye BiotechnologyN/A$2.51-4.9%N/AN/A$118.39M$186.36M0.00278Gap DownIKTInhibikase Therapeutics0.0057 of 5 stars$1.58-2.5%N/AN/A$117.74M$260K0.006News CoverageSRZNSurrozen2.214 of 5 stars$13.60-1.4%$38.50+183.1%+30.5%$116.55M$12.62M-0.9480Positive NewsPLRXPliant Therapeutics3.9923 of 5 stars$1.88+14.3%$8.19+336.7%-87.7%$115.11M$1.58M-0.5590Options VolumeHigh Trading VolumeARTVArtiva Biotherapeutics3.8871 of 5 stars$4.72-3.9%$18.25+286.7%-55.8%$114.09M$250K0.0081Gap Up Related Companies and Tools Related Companies VIRI Competitors MGX Competitors HURA Competitors ZNTL Competitors ABOS Competitors ZYBT Competitors IKT Competitors SRZN Competitors PLRX Competitors ARTV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMA) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImageneBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImageneBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
